1-4 of 4
Stephanie Dulucq, MD
Close
Save search
Follow your search
Access your saved searches in your account
Would you like to receive an alert when new items match your search?
Close Modal
Sort by
Journal Articles

ELN 2013 Response Status Criteria: Relevance For De Novo imatinib Chronic Phase Chronic Myeloid Leukemia Patients?

Gabriel Etienne, MD, PHD, Stephanie Dulucq, MD, Axelle Lascaux, MD, Anna Schmitt, MD, Audrey Bidet, Marie-Pierre Fort, Eric Lippert, Caroline Bureau, Didier Adiko, MD, Sandrine Hayette, Josy Reiffers, MD, Franck E. Nicolini, MD PhD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2013) 122 (21): 4029.
https://doi.org/10.1182/blood.V122.21.4029.4029
Published: 2013
Journal Articles

Pegylated Interferon-α 2a in Combination to Nilotinib As First Line Therapy in Newly Diagnosed Chronic Phase Chronic Myelogenous Leukemia Provides High Rates of MR 4.5 . Preliminary Results of a Phase II Study.

Franck E. Nicolini, MD, PhD, Gabriel Etienne, MD, PhD, Viviane Dubruille, MD, Lydia Roy, MD, Françoise Huguet, Laurence Legros, MD, PhD, Stephane Giraudier, MD, PhD, Valérie Coiteux, MD, Agnès Guerci-Bresler, MD, Pascal Lenain, MD, Delphine Rea, MD, PhD, Shanti Ame, MD, Pascale Cony-Makhoul, MD, Martine Gardembas, MD, Eric Hermet, MD, Philippe Rousselot, MD, PhD, Marie-Claude Gagnieu, PharmD, PhD, Stephane Morisset, Stat., Christine Pivot, Pharm., Madeleine Etienne, CRA, François Guilhot, MD, Stephanie Dulucq, MD, Francois-Xavier Mahon, MD, PhD
Journal: Blood
Blood (2012) 120 (21): 166.
https://doi.org/10.1182/blood.V120.21.166.166
Published: 2012
Journal Articles

The Month Three Major Molecular Response in Chronic Phase Chronic Myeloid Leukemia on imatinib 400 , Nilotinib and Dasatinib Is a Major Prognostic Factor for Failure-Free and Progression-Free Survival

Franck E Nicolini, MD, PhD, Sandrine Hayette, PhD, Helene Labussiere, MD, PhD, Madeleine Etienne, CRA, Marie-Pierre Fort, Elodie Gadolet, CRA, Isabelle Tigaud, MD, Kaddour Chabane, Eric Lippert, MD, Mohamad Sobh, Pharm.M., Stephanie Dulucq, MD, Stephane Morisset, Stat., Mauricette Michallet, Francois-Xavier Mahon, MD, PhD, Gabriel Etienne, MD, PhD
Journal: Blood
Blood (2011) 118 (21): 1684.
https://doi.org/10.1182/blood.V118.21.1684.1684
Published: 2011
Journal Articles

Potent Graft-Versus-Leukemia Effect After Reduced Intensity (RIC) Allogeneic Stem-Cell Transplantation (ASCT) As Post-Remission Therapy for Intermediate-Risk De-Novo Acute Myeloid Leukemia (AML) with FLT3-ITD Genotype or Wild-Type (WT) NPM1 and CEBPA without FLT3-ITD,

Gaëlle Labouré, Stephanie Dulucq, MD, Stephane Vigouroux, MD, Éric Lippert, MD, PhD, Arnaud Pigneux, MD, PhD, Reza Tabrizi, MD, Thibaut Leguay, MD, Krimo Bouabdallah, MD, Marie-Sarah Dilhuydy, MD, Anna Schmitt, Gerald Marit, MD, PhD, Francois-Xavier Mahon, MD, PhD, Noel Milpied, MD
Journal: Blood
Blood (2011) 118 (21): 4129.
https://doi.org/10.1182/blood.V118.21.4129.4129
Published: 2011